1. |
- Olsson, Anders, et al.
(författare)
-
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
- 2001
-
Ingår i: American Journal of Cardiology. - 0002-9149 .- 1879-1913. ; 88:5, s. 504-508
-
Tidskriftsartikel (refereegranskat)abstract
- Rosuvastatin is a new, synthetic, orally active statin, with marked low-density lipoprotein (LDL) cholesterol-lowering activity. We conducted 2 dose-ranging studies. In the first study, after a 6-week dietary run-in, 142 moderately hypercholesterolemic patients were randomized equally to receive double-blind placebo or rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg or open-label atorvastatin 10 or 80 mg once daily for 6 weeks, in the second study, conducted to extend the rosuvastatin dose range, 64 patients were randomized to double-blind, once-daily placebo or rosuvastatin 40 or 80 mg (1:1:2 ratio) for 6 weeks. Data from both studies were combined for analysis of lipid effects. No statistical comparison of atorvastatin arms with placebo or rosuvastatin was performed. Rosuvastatin was associated with highly significant dose-dependent reductions in LDL cholesterol compared with placebo (p <0.001), decreases ranged from 34% (1 mg) to 65% (80 mg). Linear regression analysis indicated an additional 4.5% LDL cholesterol reduction for each doubling of the rosuvastatin dose. Across the dose range, approximately 90% of LDL cholesterol reduction occurred within the first 2 weeks of treatment. Significant, dose-dependent reductions in total cholesterol and apolipoprotein B with rosuvastatin were also observed (p <0.001). High-density lipoprotein cholesterol increases and triglyceride reductions were consistently observed and statistically significant at some dose levels. All lipid ratios were significantly reduced at all rosuvastatin dose levels (p <0.001). Adverse events were similar across placebo and active treatments. No significant increases in alanine aminotransferase or creatine kinase were seen in any patient. Over 6 weeks, rosuvastatin produced large, rapid, dose-dependent LDL cholesterol reductions and was well tolerated in hypercholesterolemic patients. © 2001 by Excerpta Medica, Inc.
|
|
2. |
|
|
3. |
|
|
4. |
- Clear, A., et al.
(författare)
-
Designing Computer Science Competency Statements : A Process and Curriculum Model for the 21st Century
- 2020
-
Ingår i: Proceedings of the Working Group Reports on Innovation and Technology in Computer Science Education, ITiCSE 2020. - New York, NY, USA : Association for Computing Machinery (ACM). ; , s. 211-246
-
Konferensbidrag (refereegranskat)abstract
- The broadly influential document Computing Curricula 2005 (CC2005) is in the process of being updated through a project called Computing Curricula 2020 (CC2020). CC2020 provides a vision for the future of computing education, including a comprehensive report that contrasts curricular guidelines, and contextualizing those guidelines within the broader landscape of computing education. In the process, a framework of competency-based educational principles has been developed which is closely aligned with other skills and qualifications frameworks. This working group report demonstrates one way in which the transition from current learning-outcomes-based practices to the competency-based practices can be approached. Further, the paper discusses the challenges and insights that have emerged as the learning outcomes for various Knowledge Areas in the CS2013 report were re-expressed in terms of competencies.
|
|
5. |
- Olsson, Anders, 1940-, et al.
(författare)
-
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
- 2002
-
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 144:6, s. 1044-1051
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Despite the demonstrated benefits of low-density lipoprotein cholesterol (LDL-C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid-lowering therapy fail to achieve LDL-C goals. We compared the effects of rosuvastatin and atorvastatin in reducing LDL-C and achieving LDL-C goals in patients with primary hypercholesterolemia. Methods and Results: In this 52-week, randomized, double-blind, multicenter trial (4522IL/0026), 412 patients with LDL-C 160 to <250 mg/dL received a 5-mg dose of rosuvastatin (n = 138), a 10-mg dose of rosuvastatin (n = 134), or a 10-mg dose of atorvastatin (n = 140) for 12 weeks, during the following 40 weeks, dosages could be sequentially doubled up to 80 mg if National Cholesterol Education Program Adult Treatment Panel II (ATP-II) LDL-C goals were not achieved. At 12 weeks, 5- and 10-mg doses of rosuvastatin were associated with significantly greater LDL-C reductions than 10-mg doses of atorvastatin (46% and 50% vs 39%, both P < .001). At 12 weeks, both rosuvastatin dosages brought more patients to within ATP-II and European LDL-C goals than atorvastatin (86% and 89% vs 73% and 75%, and 86% vs 55%, respectively). At 52 weeks, compared with atorvastatin, both initial rosuvastatin treatment groups significantly reduced LDL-C (47% and 53% vs 44%, P < .05 and P < .001). Overall, more patients in the initial rosuvastatin 10-mg group achieved their ATP-II LDL-C goal than those in the initial atorvastatin 10-mg group (98% vs 87%), with 82% of patients treated with rosuvastatin achieving their goal at the 10-mg starting dosage without the need for titration, compared with 59% of patients treated with atorvastatin. Both treatments were well tolerated over 52 weeks. Conclusion: Compared with atorvastatin, rosuvastatin produced greater reductions in LDL-C, which may offer advantages in LDL-C goal attainment over existing lipid-lowering therapies.
|
|
6. |
|
|
7. |
|
|
8. |
|
|